Liposomal amphotericin b displays rapid dose-dependent activity against Candida albicans Biofilms

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2369-2371

  Ramage, Gordon ^a   Jose, Anto ^a   Sherry, Leighann ^a   Lappin, David F ^a   Jones, Brian ^b   Williams, Craig ^c  

^a GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PYRIMIDINES; TRIAZOLES;

EID: 84876204716     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02344-12     Document Type: Article

References (20)

1. Ramage G, Martinez JP, Lopez-Ribot JL. 2006. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6:979-986.
2. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, de Gaetano Donati K, La Sorda M, Spanu T, Fadda G, Cauda R, Sanguinetti M. 2007. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45:1843-1850.
3. Gagne JJ, Goldfarb NI. 2007. Candidemia in the in-patient setting: treatment options and economics. Expert Opin. Pharmacother. 8:1643-1650.
4. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. 2007. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 26:271-276.
5. Kibbler CC, Seaton S, Barnes RA, Gransden WR, Holliman RE, Johnson EM, Perry JD, Sullivan DJ, Wilson JA. 2003. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54:18-24.
6. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S. 2011. Guidelines for the prevention of intravascular catheter-related infections. Clin. Infect. Dis. 52:e162-e193.
7. Angel-Moreno A, Boronat M, Bolanos M, Carrillo A, Gonzalez S, Perez Arellano JL. 2005. Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review. J. Infect. 51:e85-e87. doi:10.1016/j .jinf.2004.08.034.
8. Viale P, Petrosillo N, Signorini L, Puoti M, Carosi G. 2001. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? Clin. Infect. Dis. 33:1947-1948.
9. Wu CY, Lee PI. 2007. Antibiotic-lock therapy and erythromycin for treatment of catheter-related Candida parapsilosis and Staphylococcus aureus infections. J. Antimicrob. Chemother. 60:706-707.
10. Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P, Whyte JA, Gow NA, Jones BL. 2007. One year prospective survey of Candida bloodstream infections in Scotland. J. Med. Microbiol. 56:1066-1075.
11. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard - third edition. CLSI document M27-A3. CLSI, Wayne, PA.
12. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
13. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
14. Schinabeck MK, Long LA, Hossain MA, Chandra J, Mukherjee PK, Mohamed S, Ghannoum MA. 2004. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob. Agents Chemother. 48:1727-1732.
15. Raad II, Hachem RY, Hanna HA, Fang X, Jiang Y, Dvorak T, Sherertz RJ, Kontoyiannis DP. 2008. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int. J. Antimicrob. Agents 32:515-518.
16. Seidler M, Salvenmoser S, Muller FM. 2010. Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model. FEMS Yeast Res. 10:492-495.
17. Toulet D, Debarre C, Imbert C. 2012. Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials? J. Antimicrob. Chemother. 67:430-432.
18. Melo AS, Colombo AL, Arthington-Skaggs BA. 2007. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob. Agents Chemother. 51:3081-3088.
19. Walker LA, Gow NAR, Munro CA. 2013. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob. Agents Chemother. 57:146-154.
20. Tumbarello M, Fiori B, Trecarichi EM, Posteraro P, Losito AR, De Luca A, Sanguinetti M, Fadda G, Cauda R, Posteraro B. 2012. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One 7:e33705. doi:10.1371/journal.pone.0033705.